Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease
Phase 2
Terminated
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: ABT-089Drug: placebo
- Registration Number
- NCT00555204
- Lead Sponsor
- Abbott
- Brief Summary
The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for Alzheimer's disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 337
Inclusion Criteria
- Patient has mild to moderate Alzheimer's disease
- Patient has been receiving a stable dose of an acetylcholinesterase inhibitor
- Patient has a MMSE score between 12 and 26
- Patient has a MHIS score of less than or equal to 4
- Females must be postmenopausal for at least two years or surgically sterile
- Patient has an identified, reliable, caregiver who will support him/her to ensure compliance with treatment and will accompany them to each outpatient visit
Read More
Exclusion Criteria
- Patient is living in a nursing home
- Patient has a history of any significant neurologic disease other than Alzheimer's disease
- Patient has any uncontrolled medical illness
- Patient uses non-prescribed drugs of abuse or has a history of drug or alcohol abuse/dependence
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description A ABT-089 - B ABT-089 - C ABT-089 - D ABT-089 - E ABT-089 - F ABT-089 - G placebo -
- Primary Outcome Measures
Name Time Method Safety and Tolerability Baseline to Final Evaluation
- Secondary Outcome Measures
Name Time Method Pharmacokinetics (how the body handles the study drug) Baseline to Final Evaluation Pharmacodynamic (how the study drug affects cognitive functions such as thinking and memory) Baseline to Final Evaluation